{"article": [{"url": "https://www.marketwatch.com/story/virs-stock-rises-as-covid-19-drug-moves-to-late-study-clinical-trial-2020-10-06", "published": 1601979080.0, "headline": "Vir's stock rises as COVID-19 drug moves to late-study clinical trial", "body": "Shares of Vir Biotechnology Inc. VIR, -1.94% gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment. The treatment, a monoclonal antibody called VIR-7831, is aimed at patients with COVID-19 who are at high risk of hospitalization. The randomized, placebo-controlled late-stage study will evaluate 1,300 non-hospitalized patients who have tested positive for COVID-19 and whether they need to be hospitalized or die within 29 days. Results are expected in January. GlaxoSmithKline GSK, +1.10% is also involved in the development of the therapy, as part of a coronavirus-focused development agreement announced by Vir and GSK in April. Vir's stock has soared 211.0% so far this year. The S&P 500 SPX, +0.87%, in comparison, has gained 5.5%."}]}